F A Diegert

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
PURPOSE The combination of etoposide (E) and cisplatin (P) is an accepted standard therapy for small-cell lung cancer (SCLC); however, the optimal sequencing and administration schedule has not been defined. This study was designed to evaluate different sequencing and administration schedules of E and P in the treatment of SCLC. PATIENTS AND METHODS Five(More)
  • 1